FDA perspective on anti-TNF treatments

Article Abstract:

The FDA believes the long-term effectiveness and safety of anti-TNF treatments for rheumatoid arthritis have not yet been demonstrated. Anti-TNF treatments are drugs that block the activity of tumor necrosis factor, which has been implicated in the development of rheumatoid arthritis.

Drug therapy, Science and technology policy, United States. Food and Drug Administration

---

Clinical implications of tumour necrosis factor alpha antagonism in patients with congestive heart failure

Article Abstract:

Drugs that block the activity of tumor necrosis factor may be beneficial in the treatment of heart failure. Levels of this immune system protein increase in heart failure, and may damage the heart further.

Care and treatment, Heart failure

---

Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors

Article Abstract:

Rheumatoid arthritis is an inflammatory disease of joints and tumor necrosis factor is believed to be the major protein involved. The role of tumor necrosis factor and its receptor is reviewed.

Causes of

Similar abstracts:

• Abstracts: More precision in diagnosing appendicitis. Indications for computed tomography in patients with minor head injury
• Abstracts: Muscle pain, fatigue, and mitochondriopathies. Clinical implications of the hemochromatosis gene. The CDKN2A tumor-suppressor locus - a tale of two proteins
• Abstracts: Continuous, noninvasive measurement of pulsus paradoxus in patients with acute asthma. Frozen oral hydration as an alternative to conventional enteral fluids
• Abstracts: Epidemic reactive arthritis. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis
• Abstracts: Mission impossible. Nursing a patient with severe facial injuries in ICU

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.